comparemela.com
Home
Live Updates
Dystrogen Therapeutics Investigational Chimeric Cell Therapy
Dystrogen Therapeutics Investigational Chimeric Cell Therapy
Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements
Results continue to support evidence for safety, tolerability, clinical efficacy, and biomarker improvements of DT-DEC01 At 6 months treated patients achieved...
Related Keywords
Poland ,
Miami ,
Florida ,
United States ,
Warsaw ,
L67 ,
Kris Siemionow ,
Dystrogen Therapeutics Corp ,
Dystrogen Therapeutics Corporation ,